EurekaMag.com logo
+ Translate

The lupus inhibitor its heterogeneity


, : The lupus inhibitor its heterogeneity. Thrombosis & Haemostasis 46(4): 734-739

The plasmas of 6 patients with prolonged activated partial thromboplastin times were studied in detail. In 5 of the 6, the Russell's viper venom and prothrombin times were likewise prolonged. Five of the patients had documented systemic lupus erythematosus; one lacked the necessary criteria for this diagnosis. On quantitation, factor XI was decreased in all 6; factors X and XII were diminished in 5 of the 6. When tested for inhibitory activity, plasma from each of the patients prolonged the celite eluate inhibition test for factor XII and/or XI inhibition. In the formation of the factor Xa-factor V-phospholipid-Ca2+ complex (prothrombinase), factors X and Xa were inhibited to a greater degree than factor V or the phospholipid. Finally, each plasma was isofocused, the inhibitory fractions were identified and the clotting factor specificity of each inhibitory peak was determined. Fractions inhibitory against factors XI and XII isofocused with the IgG in each patient's plasma. The lupus inhibitor is apparently a heterogeneous collection of inhibitors directed against factors XII, XI and X rather than a homogeneous entity.

(PDF 0-2 workdays service)

Accession: 006712445

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Coots, M.C.; Miller, M.A.; Glueck, H.I., 1981: The lupus inhibitor: a study of its heterogeneity. The plasmas of six patients with prolonged activated partial thromboplastin times were studied in detail. In five of the six, the Russell's viper venom and prothrombin times were likewise prolonged. Five of the patients had documented systemi...

Nakamura, N.; Azuma, C.; Akamizu, T.; Sugawa, H.; Matsuda, F.; Mitsuda, N.; Honjo, T.; Mori, T.; Yamaji, K., 1994: Heterogeneity and diversity of IgM and IgG lupus anticoagulants in an individual with systemic lupus erythematosus. From one patient with systemic lupus erythematosus retaining lupus anticoagulant (LAC), we established 6 Epstein-Barr virus-transformed human B cell clones secreting antibodies that affect the coagulation assay. Two and 4 of the clones secreted Ig...

Horellou, M.H.; Aurousseau, M.H.; Boffa, M.C.; Conrad, J.; Wiesel, M.L.; Samama, M., 1987: Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients. A lupus or lupus-like inhibitor was detected in 57 patients: 24 systemic lupus erythematosus, 9 autoimmune diseases, 10 lymphoproliferative disease, 11 miscellaneous diseases and 3 asymptomatic patients. No hemorrhagic diathesis was observed in sp...

Donaldson, V.H.; Bissler, J.J.; Welch, T.R.; Burton, M.F.; Davis, A.E., 1996: Antibody to C1-inhibitor in a patient receiving C1-inhibitor infusions for treatment of hereditary angioneurotic edema with systemic lupus erythematosus reacts with a normal allotype of residue 458 of C1-inhibitor. Patients with hereditary C4 deficiency are likely to have severe lupus erythematosus. A patient with hereditary angioneurotic edema (HANE) and systemic lupus erythematosus (SLE) had a chronic deficiency in C4 because the hereditary deficiency in C...

Donaldson, V.H.; Bissler, J.J.; Welch, T.R.; Burton, M.F.; Davis, A.E.IIi, 1996: Antibody to C1-inhibitor in a patient receiving C1-inhibitor infusions for treatment of hereditary angioneurotic edema with systemic lupus erythematosus reacts with a normal allotype of residue 458 of C1-inhibitor. Patients with hereditary C4 deficiency are likely to have severe lupus erythematosus. A patient with hereditary angioneurotic edema (HANE) and systemic lupus erythematosus (SLE) had a chronic deficiency in C4 because the hereditary deficiency in C...

Manoharan, A.; Gibson, L.; Rush, B.; Feery, B.J., 1977: Recurrent venous thrombosis with a "lupus" coagulation inhibitor in the absence of systemic lupus. A young man presenting with recurrent deep venous thrombosis was found to have a lupus type coagulation inhibitor. He showed neither clinical nor serological evidence of systemic lupus. The value of the Russell viper venom coagulation time in the...

Gårdlund, B., 1984: The lupus inhibitor in thromboembolic disease and intrauterine death in the absence of systemic lupus. This study describes the use of a modified dilute thromboplastin assay for demonstration of the lupus coagulation inhibitor in plasma. A one-stage clotting inhibition assay is used in which the ability of the test plasma to prolong the clotting ti...

Constans, J.; L.H.rissier, A.; Vergnes, C.; Roudaut, R.; Durandet, P.; Gosse, P.; Dallocchio, M., 1992: Circulating lupus coagulation inhibitor in two sisters, one with disseminated lupus erythematosus and the other with immunologic thrombocytopenic purpura. Familial cases of lupus anticoagulant were rarely described. We report the observation of two sisters with lupus anticoagulant, one with thrombocytopenic purpura and the other with systemic lupus erythematosus.

Fernandez, C.; Roldan, V.; Marco, P.; Verdu, J.; Batlle, E.; Pascual, E., 1998: High amounts of tissue factor pathway inhibitor in lupus patients and the relationships with lupus activity and damage. Arthritis & Rheumatism 41(9 SUPPL ): S218, Sept

Ho, C.H.; Chau, W.K.; Chiu, C.F.; Hsu, H.C.; Tsai, S.T., 1996: Test heterogeneity of the lupus anticoagulant Comparison of various La test in 102 cases of systemic lupus erythematosus. Fibrinolysis 10(SUPPL 3): 100